Table 1.
Study population in chronological order of admission: clinical features.
| Pt | Sex | Age | Ongoing IS therapy | Days from last IS administration | Diseases | Days to hospitalization from symptom onset | Days to hospitalization from first NPS | MoAbs | Hyperimmuneplasma | VS | Lenght of stay | Days to PCR negativization | Clinical Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 54 | Ocrelizumab | 105 | MS | 20 | 21 | CAS+IMD | No | NONE | 51 | 55 | RECOVERY |
| 2 | M | 54 | Rituximab | 163 | NHL | 31 | 17 | CAS+IMD | No | NIV | 32 | 68 | RECOVERY |
| 3 | M | 39 | Rituximab | >12 y | NHL | 54 | 63 | NO | Yes | NIV | 92 | 85 | RECOVERY |
| 4 | M | 66 | Obinutumab | NA | NHL | 52 | 100 | CAS+IMD | Yes | VM | 19 | 168 | RECOVERY |
| 5 | M | 65 | Rituximab | 60 | NHL | 33 | 33 | NO | Yes | VM | 19 | 50 | RECOVERY |
| 6 | M | 67 | Rituximab | 106 | NHL | 3 | 114 | NO | Yes | VM | 30 | 123 | RECOVERY |
| 7 | M | 59 | Rituximab | 150 | NHL | 120 | 6 | NO | Yes | VM | 15 | 43 | RECOVERY |
| 8 | F | 24 | Rituximab | 76 | WG | 78 | 6 | BAM+ETE | No | VM | 11 | 90 | RECOVERY |
| 9 | F | 25 | Ocrelizumab | 13 | MS | 12 | 78 | CAS+IMD | No | VM | 19 | 38 | RECOVERY |
| 10 | F | 66 | Rituximab | 180 | NHL | 7 | 7 | CAS+IMD | No | c-PAP | 26 | 76 | RECOVERY |
| 11 | F | 77 | Rituximab | 217 | NHL | 10 | 8 | CAS+IMD | Yes | NIV | 51 | 90 | RECOVERY |
| 12 | M | 35 | Rituximab | 126 | PS | 46 | 47 | CAS+IMD | No | c-PAP | 62 | 61 | RECOVERY |
| 13 | M | 54 | Rituximab | 11 y | NHL | 120 | 119 | BAM+ETE | Yes | NIV | 6 | 119 | RECOVERY |
| 14 | F | 68 | Rituximab | 66 | CLL | 36 | 36 | CAS+IMD | No | c-PAP | 44 | 60 | RECOVERY |
| 15 | M | 68 | Rituximab | NA | NHL | 13 | 10 | NO | No | VM | 30 | NA | DEATH |
| 16 | M | 73 | Daratumumab | NA | MM | 2 | 11 | CAS+IMD | No | VM | 38 | 36 | RECOVERY |
| 17 | F | 76 | Rituximab | NA | RA | 9 | 9 | CAS+IMD | No | VM | 11 | 37 | RECOVERY |
| 18 | M | 83 | None | >20 y | NHL | 9 | 9 | CAS+IMD | No | VM | 16 | 31 | RECOVERY |
| 19 | M | 63 | None | 2 y | NHL | 41 | 2 | CAS+IMD | No | VM | 35 | 36 | RECOVERY |
| 20 | F | 77 | Daratumumab | 30 | MM | 3 | 2 | CAS+IMD | No | c-PAP | 30 | 39 | RECOVERY |
| 21 | F | 56 | Rituximab | 14 | WG | 4 | 4 | CAS+IMD | No | VM | 17 | 28 | RECOVERY |
IS, immunosoppressive; NPS, nasopharyngeal swab; MoAbs, monoclonal antibodies; CAS, casirivimab, IMD, imdevimab; BAM, bamlanivimab; ETE, etesevimab; VS, ventilatory support; MS, multiple sclerosis; NHL, non-Hodgkin’s lymphoma; PS, psoriatic arthritis; WG, Wegener granulomatosis; MM, multiple myeloma; VM, venturi mask; c-PAP, continuous positive air pressure; NIV, non-invasive ventilation; IOT, orotracheal intubation; NA, not available.